

ISIS Trials Publications List

- ISIS-1 Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1
Lancet. 1986 Jul 12;**2**(8498):57-66
[https://doi.org/10.1016/S0140-6736\(86\)91607-7](https://doi.org/10.1016/S0140-6736(86)91607-7)
- ISIS Collaborative Group. Randomized factorial trial of high-dose intravenous streptokinase, of oral aspirin and of intravenous heparin in acute myocardial infarction. ISIS (International Studies of Infarct Survival) pilot study
Eur Heart J. 1987 Jun;**8**(6):634-642
<https://doi.org/10.1093/oxfordjournals.eurheartj.a062334>
- ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
Lancet. 1988 Aug 13;**2**(8607):349-360
[https://doi.org/10.1016/S0140-6736\(88\)92833-4](https://doi.org/10.1016/S0140-6736(88)92833-4)
- Collins R, Peto R, Sleight P. Significant reduction in mortality with streptokinase given 7-24 hours after pain onset
Lancet. 1988 Nov 19;**2**:1187-1188
[https://doi.org/10.1016/S0140-6736\(88\)90249-8](https://doi.org/10.1016/S0140-6736(88)90249-8)
- Collins R, Julian D. British Heart Foundation surveys (1987 and 1989) of United Kingdom treatment policies for acute myocardial infarction
Br Heart J. 1991;**66**:250-255
<https://dx.doi.org/10.1136/hrt.66.3.250>
- Peto R. ISIS-3 shows similar results with different thrombolytic agents
AFP. 1991 May;**43**:1747
Not available online
- Collins R, Sleight P. ISIS-3 – Reply
JACC. 1991 Oct;**18**(4):1148
[https://doi.org/10.1016/0735-1097\(91\)90782-5](https://doi.org/10.1016/0735-1097(91)90782-5)
- ISIS-3 Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction
Lancet. 1992 Mar 28;**339**(8796):753-770.
[https://doi.org/10.1016/0140-6736\(92\)91893-D](https://doi.org/10.1016/0140-6736(92)91893-D)
- ISIS-2 Collaborative Group. Morning peak in the incidence of myocardial infarction: experience in the ISIS-2 trial
Eur Heart J. 1992 May;**13**:594-598
<https://doi.org/10.1093/oxfordjournals.eurheartj.a060221>

- Collins R *et al.* *After ISIS-3 – Reply*
Lancet. 1992 May 16;**339**(8803):1225-1227
[https://doi.org/10.1016/0140-6736\(92\)91161-Z](https://doi.org/10.1016/0140-6736(92)91161-Z)
- Collins R, Peto R, Parish S, Sleight P. ISIS-3 and GISSI-2: no survival advantage with tissue plasminogen activator over streptokinase, but a significant excess of strokes with tissue plasminogen activator in both trials
Am J Cardiol. 1993 May 1;**71**(12):1127-1130.
[https://doi.org/10.1016/0002-9149\(93\)90591-Y](https://doi.org/10.1016/0002-9149(93)90591-Y)
- Flather M, Pipilis A, Collins R, Budaj A, Hargreaves A, Kolettis T, Jacob A, Millane T, Fitzgerald L, Cedro K, et al. Randomized controlled trial of oral captopril, of oral isosorbide mononitrate and of intravenous magnesium sulphate started early in acute myocardial infarction: safety and haemodynamic effects: ISIS-4 (Fourth International Study of Infarct Survival) Pilot Study Investigators.
Eur Heart J. 1994 May;**15**(5):608-619
<https://doi.org/10.1093/oxfordjournals.eurheartj.a060556>
- ISIS-4 Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction
Lancet. 1995 Mar 18;**345**(8951):669-685
[https://doi.org/10.1016/S0140-6736\(95\)90865-X](https://doi.org/10.1016/S0140-6736(95)90865-X)
- Collins R, Peto R, Sleight P for the ISIS-4 Collaborative Group. ISIS-4 - Reply
Lancet. 1995 May 27;**345**(8961):1374 – 1375
[https://doi.org/10.1016/S0140-6736\(95\)92575-9](https://doi.org/10.1016/S0140-6736(95)92575-9)
- Parish S, Collins R, Peto R, Youngman L, Barton J, Jayne K, Clarke R, Appleby P, Lyon V, Cederholm-Williams S. Cigarette smoking, tar yields, and non-fatal myocardial infarction: 14,000 cases and 32,000 controls in the United Kingdom. The International Studies of Infarct Survival (ISIS) Collaborators
BMJ. 1995 Aug 19; **311**(7003): 471–477.
<https://doi.org/10.1136/bmj.311.7003.471>
- ISIS-3 Collaborative Group. A comparison of the early outcome of acute myocardial infarction in women and men
NEJM. 1998 Jan 1;**338**:8-14
<https://doi.org/10.1056/nejm199801013380102>
- Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
BMJ. 1998 May 2;**316**(7141):1337-1343
<https://doi.org/10.1136/bmj.316.7141.1337>

- Danesh J, Youngman L, Clark S, Parish S, Peto R, Collins R for the International Studies of Infarct Survival (ISIS) Collaborative Group. *Helicobacter pylori* infection and early onset myocardial infarction: case-control and sibling pairs study
BMJ. 1999 Oct 30; **319**: 1157-1162
<https://doi.org/10.1136/bmj.319.7218.1157>
- Danesh J, Collins R. *Helicobacter pylori* and myocardial infection - Exclusion criteria were inappropriate – Reply
BMJ. 2000 Mar 18; **320**:799
<https://doi.org/10.1136/bmj.320.7237.799>
- Keavney B, McKenzie C, Parish S, Palmer A, Clark S, Youngman L, Delépine M, Lathrop M, Peto R, Collins R. Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) Collaborators
Lancet. 2000 Feb 5; **355**(9202):434-442
[https://doi.org/10.1016/S0140-6736\(00\)82009-7](https://doi.org/10.1016/S0140-6736(00)82009-7)
- Keavney B, Youngman L, Palmer A, Parish S, Clark S, Delépine M, Lathrop M, Peto R, Collins R. Large-scale test of association between myocardial infarction, plasma lipid levels and apolipoprotein E e2/e3/e4 polymorphism in about 11,000 cases and controls
Eur Heart J. 2000; **21**: 249
Not available online
- Keavney B, Parish S, Palmer A, Clark S, Youngman L, Danesh J, McKenzie C, Delépine M, Lathrop M, Peto R, Collins R, for the International Studies of Infarct Survival (ISIS) Collaborators. Large-scale evidence that the cardiotoxicity of smoking is not significantly modified by the apolipoprotein E epsilon2/epsilon3/epsilon4 genotype
Lancet. 2003 Feb 1; **361**: 396-98
[https://doi.org/10.1016/S0140-6736\(03\)12386-0](https://doi.org/10.1016/S0140-6736(03)12386-0)
- Keavney B, Parish S, Lathrop M, Peto R, Collins R. In search of genetic precision - Reply
Lancet. 2003 May 31; **361**: 1909-10
[https://doi.org/10.1016/S0140-6736\(03\)13518-0](https://doi.org/10.1016/S0140-6736(03)13518-0)
- Keavney B, Palmer A, Parish S, Clark S, Youngman L, Danesh J, McKenzie C, Delepine M, Lathrop M, Peto R, *et al*. Lipid-related genes and myocardial infarction in 4685 cases and 3460 controls: discrepancies between genotype, blood lipid concentrations and coronary disease risk.
Int J Epidemiol. 2004 Oct; **33**(5): 1002-13. Epub 2004 Jul 15
<https://doi.org/10.1093/ije/dyh275>
- Clarke R, Xu P, Bennett D, Lewington S, Zondervan K, Parish S, Palmer A, Clark S, Cardon L, Peto R, Lathrop M, Collins R; International Study of Infarct Survival (ISIS) Collaborators. Lymphotoxin- α gene and risk of myocardial infarction in 6,928 cases and 2,712 controls in the ISIS case-control study
PLoS Genet. 2006 Jul; **2**(7):e107
<https://doi.org/10.1371/journal.pgen.0020107>

- Keavney B, Danesh J, Parish S, Palmer A, Clark S, Youngman L, Delépine M, Lathrop M, Peto R, Collins R. Fibrinogen and coronary heart disease: test of causality by 'Mendelian randomization' *Int J Epidemiol.* 2006 Aug;**35**(4):935-43. Epub 2006 Jul 26
<https://doi.org/10.1093/ije/dyl114>
- Bennett DA, Xu P, Clarke R, Zondervan K, Parish S, Palmer A, Cardon L, Peto R, Lathrop M, Collins R. The exon 1-8C/G SNP in the PSMA6 gene contributes only a small amount to the burden of myocardial infarction in 6946 cases and 2720 controls from a United Kingdom population. *Eur J Hum Genet.* 2008 Apr;**16**(4):480-6
<https://doi.org/10.1038/sj.ejhg.5201948>
- Parish S, Peto R, Palmer A, Clarke R, Lewington S, Offer A, *et al.* The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls
Eur Heart J. 2009 Sep 30; **30**;(17);2137-2146
<https://doi.org/10.1093/eurheartj/ehp221>
- Clarke R, Peden JF, Hopewell, JC, Kyriakou T, Goel A, Heath SC, Parish S *et al.* Genetic variants associated with Lp(a) lipoprotein level and coronary disease.
New Engl J Med. 2009 Dec 24; **361**;(26);2518-2528
<https://doi.org/10.1056/NEJMoa0902604>